
Novel ADC IBI354 Drives Responses in Pretreated HER2+ Advanced Breast Cancer
Treatment with the novel antibody-drug conjugate (ADC) IBI354 was safe and had antitumor activity in patients with pretreated HER2-positive advanced breast cancer, according to updated findings from a phase 1 trial (NCT05636215). Data presented at the 2025 …